Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.

LATEST LUNG CANCER CONTENT

With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy

In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade

ROS1+ NSCLC: Key Takeaways From Case-Based Roundtables With Dr Santos

The Gap Between What Oncologists Have Been Prescribing and What the ROS1 Data Now Supports

TMB, Tumor Burden, and Tailoring Immunotherapy in Lung Cancer

Checkpoint Inhibitors in Lung Cancer: When One Drug Isn't Enough

Taletrectinib and Brain Metastases in Non–Small Cell Lung Cancer

Clinical Utility of KEAP1 and STK11 in NSCLC

CASE-BASED ROUNDTABLES

Selecting Targeted Therapy for Advanced ROS1+ NSCLC

Small Cell Lung Cancer Treated in Second Line and Later

September 19, 2025

Therapies Reducing Adverse Events in Extensive-Stage SCLC

August 12, 2025

Using ctDNA Molecular Residual Disease Testing in Lung Cancer

October 31, 2024

Patients With ALK+ Lung Cancer Given Targeted Therapy

ROS1+ NSCLC Treatment Choices for First-Line and Beyond

December 18, 2023

Later-Line KRAS-Targeted Treatments Available in Lung Cancer

Targeted Therapy Options for Patients With KRAS-Mutated NSCLC

December 07, 2022

Management and Treatment of Patients With Exon 20 Non–Small Cell Lung Cancer

September 14, 2022

Squamous NSCLC Treatments Incorporating Immunotherapy Combinations

Treating Patients With NSCLC and High PD-L1 Expression in the First Line

First-Line Therapy With Bispecific Antibody for EGFR-Mutated NSCLC

Treating Early-Stage Lung Cancer With Immunotherapies

Late-Stage Therapeutic Options in Lung Cancer

January 19, 2022

Targeting MET Exon 14 Skipping Mutations in NSCLC

November 12, 2021